Dyne Therapeutics, Inc.DYNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank23
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P23
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthDecelerating
PeriodValue
Q4 2025-1.84%
Q3 2025-2.03%
Q2 2025-6.77%
Q1 202530.12%
Q4 2024-11.85%
Q3 202449.05%
Q2 202439.79%
Q1 2024-24.31%
Q4 20236.50%
Q3 2023-6.56%
Q2 202357.53%
Q1 202313.09%
Q4 2022-4.27%
Q3 2022-25.70%
Q2 202265.26%
Q1 2022-33.25%
Q4 202115.86%
Q3 202152.94%
Q2 202128.17%
Q1 2021-15.72%
Q4 2020128.31%
Q3 202031.97%
Q2 202020.45%
Q1 202042.97%
Q4 201942.82%
Q3 201956.99%
Q2 20190.00%
Q1 20190.00%
Q4 20170.00%
Q3 20170.00%
Q2 20170.00%
Q1 20170.00%
Q4 20160.00%
Q3 20160.00%
Q2 20160.00%
Q1 20160.00%
Q4 20150.00%
Q3 20150.00%
Q2 20150.00%
Q1 20150.00%